Loading clinical trials...
Loading clinical trials...
Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Conditions
Interventions
pembrolizumab
gemcitabine
+3 more
Locations
10
United States
City of Hope Cancer Center (Data Collection Only)
Duarte, California, United States
Stanford University Medical Center
Stanford, California, United States
University of Miami
Miami, Florida, United States
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States
Start Date
August 1, 2018
Primary Completion Date
August 1, 2026
Completion Date
August 1, 2026
Last Updated
April 16, 2026
NCT06870760
NCT06090539
NCT07260812
NCT07523555
NCT05529069
NCT06189391
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions